It included about 35,000 individuals with T2DM, of whom only 1.8% in the SGLT2 inhibitor group developed all-cause dementia, compared to 4.7% in the sulfonylurea group [9]. Here, SLC5A2 is linked to type 2 diabetes mellitus.